Hacker News Reader

I have a hard time believing that large pharma research labs are limiting themselves to single loci for a given disease phenotype. But if they are, it makes sense why YC would see value in this.

View on HN

They haven't for a while. Some of the claims, at least in this story, are way over the top.

They aren't

I'm going to presume that I don't really understand the company then, because the founders and advisers should certainly know more than I do about drug discovery.

> the founders and advisers should certainly know more than I do about drug discovery

Unfortunately, the operative word here appears to be "should."

We are definitely not experts in regards to pharma (neither Alice or I have experience working in pharma) but our advisors include pharma consultants and senior scientists. We're constantly engaging them and meeting with pharma execs and scientists almost daily to learn what has and hasn't worked, and have received a lot of feedback about how to bring potential new drugs to patients. There's a line between being naive and being jaded and we are trying to stick to being as realistic as possible, and value any new information or feedback, if you know anything that's contrary to our experience.

Reply on news.ycombinator.com